Shares of Avanir Pharmaceuticals Inc. nearly doubled as the company rapidly shifted into commercialization mode following FDA approval late Friday of Nuedexta (dextromethorphan hydrobromide and quinidine sulfate), the first and only FDA-approved treatment for pseudobulbar affect (PBA). (BioWorld Today) Read More
